(Q34671567)

3 August 2017

1 reference

title

Management of dyslipidemia. (English)

1 reference

3 August 2017

1 reference

Antonio M Gotto

1

1 reference

PubMed ID

12049990

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

American Journal of Medicine

3 August 2017

1 reference

3 August 2017

112 Suppl 8A

1 reference

3 August 2017

10S-18S

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Drug treatment of lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Mechanism of action of fibrates on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Regulation of lipid and lipoprotein metabolism by PPAR activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Genes involved in initial steps of bile acid synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Mechanism of action of bile acid sequestrants and other lipid-lowering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Systematic review on the risk and benefit of different cholesterol-lowering interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Structure of the human acyl-CoA:cholesterol acyltransferase-2 (ACAT-2) gene and its relation to dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Inhibitory effect of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Novel effects of the acyl-coenzyme A:Cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

Novel lipid-regulating drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

High-density lipoprotein: gene-based approaches to the prevention of atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

ABC1: the gene for Tangier disease and beyond

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901085-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(02)01085-9

1 reference

3 August 2017

1 reference

PubMed ID

12049990